U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07390838) titled 'A Study of SH009 Injection in Patients With Advanced Solid Tumors.' on Jan. 13.
Brief Summary: Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
Study Start Date: May 16, 2025
Study Type: INTERVENTIONAL
Condition:
Liver Cancer (Locally Advanced or Metastatic)
Lung Cancer (NSCLC)
Head and Neck Cancer Squamous Cell Carcinoma
Breast Cancer (Locally Advanced or Metastatic)
Esophageal Cancer
Gastric Cancer (GC)
Solid Tumor Malignancies
Intervention:
DRUG: SH009
The dosage of SH009 is 40 mg/kg QW with a treatment cycle of 28 days
Recruitment Status: RECRUITING
Sponsor: Nanjing Sanh...